Dr Martin Everett

Martin has over 30 years’ experience in academia, pharmaceutical R&D (GSK) and biotechnology (MerLion, ANTABIO) as a drug discovery scientist, with a particular interest in antibiotic resistance/persistence mechanisms. At GSK he managed a high-throughput screening group and led several lead discovery projects. At MerLion he was Head of Research leading a multi-disciplinary team discovering novel natural product derived compounds. At ANTABIO, Martin is the CSO and heads up all R&D activities, which includes teams in France, UK and USA. He is PI for ANTABIO’s Pseudomonas Elastase inhibitor programme, supported by CARB-X.